484 related articles for article (PubMed ID: 26092348)
21. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
[TBL] [Abstract][Full Text] [Related]
22. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
23. The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
Kvartsberg H; Lashley T; Murray CE; Brinkmalm G; Cullen NC; Höglund K; Zetterberg H; Blennow K; Portelius E
Acta Neuropathol; 2019 Jan; 137(1):89-102. PubMed ID: 30244311
[TBL] [Abstract][Full Text] [Related]
24. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
[TBL] [Abstract][Full Text] [Related]
25. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
26. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
27. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
[TBL] [Abstract][Full Text] [Related]
28. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
[TBL] [Abstract][Full Text] [Related]
30. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
[TBL] [Abstract][Full Text] [Related]
31. Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Dulewicz M; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172069
[TBL] [Abstract][Full Text] [Related]
32. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays.
Öhrfelt A; Dumurgier J; Zetterberg H; Vrillon A; Ashton NJ; Kvartsberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
Alzheimers Res Ther; 2020 Dec; 12(1):168. PubMed ID: 33353563
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
34. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
[TBL] [Abstract][Full Text] [Related]
35. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia.
Das S; Goossens J; Jacobs D; Dewit N; Pijnenburg YAL; In 't Veld SGJG; Teunissen CE; Vanmechelen E
Alzheimers Res Ther; 2023 Mar; 15(1):62. PubMed ID: 36964594
[TBL] [Abstract][Full Text] [Related]
36. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
37. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
39. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
[TBL] [Abstract][Full Text] [Related]
40. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
